Saniona AB (SANION) AI Stock Analysis

• Market Cap: €2.18B
• Dividend Yield: N/A
• Average Volume (3M): 1.06M
• Price to Earnings (P/E): 8.1
• Beta (1Y): -1.02
• Revenue Growth: 2687.51%
• EPS Growth: N/A
• Country: SE
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 2.39
• Shares Outstanding: 138,030,140
• 10 Day Avg. Volume: 913,988
• 30 Day Avg. Volume: 1,064,614
• PEG Ratio: -0.02
• Price to Book (P/B): 3.69
• Price to Sales (P/S): 2.56
• P/FCF Ratio: 3.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 76 Outperform
• Price Target: kr20.00 ▼(-8.68% Downside)

Saniona AB's strong financial performance and undervaluation are the most significant factors driving the stock's score. The company's impressive financial recovery and growth, combined with positive technical indicators, suggest a favorable outlook. The absence of earnings call data and corporate events does not detract from the overall positive assessment.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market traction and the successful execution of Saniona's business strategy in the biotechnology sector.

Cash Generation

The turnaround in free cash flow underscores Saniona's ability to generate cash efficiently, enhancing its financial flexibility and supporting future growth initiatives.

Balance Sheet Health

A low debt-to-equity ratio reflects reduced financial risk and a strong capital structure, positioning Saniona well for sustainable long-term growth.

Negative Factors

Industry Risks

Biotechnology companies face high regulatory and development risks, which can impact long-term stability and require continuous innovation and investment.

Employee Base

A small employee base may limit operational capacity and scalability, potentially hindering the company's ability to manage growth and complex projects effectively.

Profitability Concerns

While high margins indicate strong performance, they may not be sustainable long-term in a competitive industry, posing risks to future profitability.

Saniona AB Business Overview & Revenue Model

Company Description

Saniona AB is a biotechnology company focused on developing innovative treatments for rare diseases and neurological disorders. Based in Sweden, the company leverages its proprietary platform to discover and develop novel drug candidates, primarily targeting ion channels and receptors involved in various neurological and metabolic conditions. Saniona's core products are in different stages of clinical development, aimed at addressing significant unmet medical needs in areas such as obesity and pain management.

How the Company Makes Money

Saniona AB generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which provide funding for the development of its drug candidates in exchange for milestone payments and royalties on future sales. Additionally, the company may receive upfront payments as part of licensing agreements for its proprietary technologies and products. As Saniona progresses its candidates through clinical trials, it can also attract further investments and grants aimed at supporting its research and development efforts, contributing to its overall earnings potential.

Saniona AB Financial Statement Overview

Summary

Saniona AB has shown a solid financial recovery and growth trajectory, with significant improvements across all financial statement metrics. The company has successfully transitioned from a loss-making position to profitability, enhanced its financial stability, and optimized cash flows. While there are inherent risks in the biotechnology industry, the company's strong balance sheet and cash flow position provide a cushion against potential volatility.

Income Statement

Saniona AB has demonstrated impressive revenue growth, increasing from SEK 16.84M in 2023 to SEK 334.67M in 2024, showcasing a strong market traction in the biotechnology space. The gross profit margin improved significantly to 98.5% in 2024 from 69.9% in 2023, reflecting efficient cost management. Additionally, the net profit margin turned positive to 56.4% in 2024, indicating profitability after years of losses. However, the EBIT and EBITDA margins are high at 72.3% and 76.1%, respectively, showing robust operating performance.

Balance Sheet

The company's balance sheet shows strong financial stability, with a positive shift in stockholders' equity from negative SEK 21.94M in 2023 to positive SEK 231.82M in 2024. The debt-to-equity ratio decreased significantly to 0.05, underscoring a low leverage position which reduces financial risk. The equity ratio improved to 68.2%, highlighting a solid capital structure. This healthy financial position suggests reduced risk and potential for future growth.

Cash Flow

Saniona AB's cash flow statements reflect a remarkable turnaround. The free cash flow increased from negative SEK 85.66M in 2023 to positive SEK 249.07M in 2024, signaling strong cash generation capabilities. The operating cash flow to net income ratio is 1.32, indicating efficient cash management in relation to profits. Moreover, the free cash flow to net income ratio is 1.32, suggesting a healthy conversion of earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	339.70M	334.67M	16.84M	15.28M	10.48M	8.20M
Gross Profit	334.48M	329.58M	11.78M	10.81M	5.85M	4.95M
EBITDA	276.93M	251.90M	-68.28M	-198.41M	-398.86M	-65.07M
Net Income	214.40M	188.71M	-95.81M	-245.36M	-410.90M	-73.43M
Balance Sheet
Total Assets	421.75M	339.73M	64.14M	153.70M	440.25M	692.18M
Cash, Cash Equivalents and Short-Term Investments	308.24M	303.26M	30.96M	111.71M	356.86M	573.87M
Total Debt	6.41M	10.50M	71.41M	81.52M	99.77M	47.51M
Total Liabilities	65.41M	107.92M	86.08M	100.99M	158.25M	88.72M
Stockholders Equity	356.34M	231.82M	-21.94M	52.71M	282.00M	603.46M
Cash Flow
Free Cash Flow	183.62M	249.07M	-85.66M	-282.52M	-346.52M	-179.71M
Operating Cash Flow	256.47M	249.20M	-85.53M	-281.54M	-345.04M	-174.71M
Investing Cash Flow	-72.86M	-124.00K	-129.00K	6.84M	43.16M	99.51M
Financing Cash Flow	75.20M	23.25M	-7.97M	-20.52M	50.60M	621.18M

Saniona AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 21.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SANION, the sentiment is Positive. The current price of 21.9 is above the 20-day moving average (MA) of 18.28, above the 50-day MA of 16.08, and above the 200-day MA of 10.82, indicating a bullish trend. The MACD of 1.62 indicates Negative momentum. The RSI at 77.92 is Negative, neither overbought nor oversold. The STOCH value of 92.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SANION.

Saniona AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	76 Outperform	€2.18B	8.11	167.77%	―	2687.51%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONCO	50 Neutral	kr1.38B	―	―	―	131.20%	32.28%
SYNACT	48 Neutral	€1.22B	-10.49	-58.41%	―	―	48.14%
XBRANE	48 Neutral	€217.39M	1.17	-16.90%	―	4.64%	―
XSPRAY	47 Neutral	€1.04B	-3.56	-35.03%	―	―	25.14%
CANTA	31 Underperform	€815.45M	-4.15	81.19%	―	―	―

Saniona AB Corporate Events

Saniona AB Strengthens CNS Therapy Pipeline with Strategic Partnerships

Saniona AB reported significant financial growth in Q3 2025, highlighted by a lucrative licensing agreement with Jazz Pharmaceuticals for SAN2355, aimed at treating epilepsy. This partnership, alongside the selection of SAN2668 for severe pediatric epilepsy syndromes, underscores Saniona’s strategic positioning to leverage global demand for innovative CNS treatments, potentially unlocking substantial long-term value for shareholders.

Saniona Announces Q3 Investor Call for 27 November 2025

Saniona AB has announced a Q3 investor call scheduled for 27 November 2025, where management will present results and provide a company update. This call is an opportunity for stakeholders to gain insights into Saniona’s operational progress and strategic direction, potentially impacting its industry positioning and stakeholder interests.

Saniona AB Announces Nomination Committee for 2026 AGM

Saniona AB has announced the composition of its Nomination Committee for the Annual General Meeting 2026, which will include representatives appointed by the company’s two largest shareholders and the Chairman of the Board. The committee is tasked with preparing proposals for the election of board members and other key roles, as well as remuneration and auditor appointments, which will be presented at the meeting in May 2026.